Oragenics Appoints Seasoned Vaccine Executive Kimberly Murphy as President and Chief Executive Officer
23 Juin 2022 - 10:30PM
Business Wire
Oragenics, Inc. (NYSE American: OGEN) (“Oragenics” or the
“Company”), a biotech company dedicated to fighting infectious
diseases including coronaviruses, announces the appointment of Ms.
Kimberly M. Murphy, member of the Board of Directors, as President
and Chief Executive Officer effective June 23, 2022. Ms. Murphy
brings more than 25 years of vaccine industry experience at leading
pharmaceutical companies including serving as a key leader in the
successful US and Global launch of Merck’s HPV/Gardasil Franchise.
Ms. Murphy joined Oragenics’ Board of Directors in 2020.
“As a Board Member, Ms. Murphy’s extensive experience in the
vaccine industry has provided valuable insight for Oragenics’
corporate and development strategies. Her proven leadership and
execution will continue to elevate the potential of the Company and
our pipeline programs,” commented Fred Telling, Chairman of Board
of Directors. “We are excited to have her strategic vision further
implemented serving as President and Chief Executive Officer.”
“I am honored to be appointed as the President and Chief
Executive Officer and excited to create additional meaningful
impact to accelerate growth and lead our team,” said Kimberly
Murphy, CEO. “I look forward to cultivating our strategic business
and development objectives and creating value for our stakeholders
opportunistically.”
Most recently Ms. Murphy served as Vice President of the
Influenza Franchise and Global Vaccine Commercialization Leader at
GSK, with responsibility for the global influenza vaccines business
and also served as Vice President and Global Marketing Head for
GSK’s shingles vaccine, SHINGRIX. Earlier Ms. Murphy was Vice
President and Lead for the North America Vaccines Integration
Planning Team where she integrated GSK’s acquisition of Novartis
AG’s vaccine division and served as Vice President of U.S. Vaccines
Customer Strategy and as Senior Director of U.S. Influenza
Portfolio Strategy. She also had distinguished vaccine leadership
careers at Merck & Co., Inc. and Novartis.
Ms. Murphy currently serves as a Director of Blue Water
Vaccines, Inc. (NASDAQ: BWV) and as Chairperson of Clarus
Therapeutics Holdings Inc. (NASDAQ: CRXT). She previously served in
Board and advisory roles for a privately held vaccine development
company, the Biotechnology Industry Organization, the Biodefense
Advisory Council and the Saint Joseph’s University Pharmaceutical
& Healthcare Marketing MBA Program.
Ms. Murphy holds a BA from Old Dominion University and an MBA
from Saint Joseph’s University, and completed the Marketing
Excellence Program at the Wharton School of the University of
Pennsylvania.
About Oragenics, Inc.
Oragenics, Inc. is a development-stage company dedicated to
fighting infectious diseases including coronaviruses and
multidrug-resistant organisms. Its lead product is NT-CoV2-1, an
intranasal vaccine candidate to prevent COVID-19 and variants of
the SARS-CoV-2 virus. The NT-CoV2-1 program leverages coronavirus
spike protein research licensed from the National Institutes of
Health (NIH) and the National Research Council of Canada (NRC) with
a focus on reducing viral transmission and offering a more
patient-friendly intranasal administration. Its lantibiotics
program features a novel class of antibiotics against bacteria that
have developed resistance to commercial antibiotics. For more
information about Oragenics, please visit www.oragenics.com.
Forward-Looking Statements
This communication contains “forward-looking statements” within
the meaning of the safe harbor provisions of the U.S. Private
Securities Litigation Reform Act of 1995. These forward-looking
statements are based on management’s beliefs and assumptions and
information currently available. The words "believe," "expect,"
"anticipate," "intend," "estimate," "project" and similar
expressions that do not relate solely to historical matters
identify forward-looking statements. Investors should be cautious
in relying on forward-looking statements because they are subject
to a variety of risks, uncertainties, and other factors that could
cause actual results to differ materially from those expressed in
any such forward-looking statements. These factors include, but are
not limited to, the following: the Company’s ability to advance the
development of its vaccine candidate and lantibiotics candidate
under the timelines and in accord with the milestones it projects;
the Company’s ability to obtain funding, non-dilutive or otherwise,
for the development of the vaccine and lantibiotic product
candidates, whether through its own cash on hand, or another
alternative source; the regulatory application process, research
and development stages, and future clinical data and analysis
relating to vaccines and lantibiotics, including any meetings,
decisions by regulatory authorities, such as the FDA and
investigational review boards, whether favorable or unfavorable;
the potential application of our vaccine candidate to variants and
other coronaviruses; the Company’s ability to obtain, maintain and
enforce necessary patent and other intellectual property
protection; the nature of competition and development relating to
COVID-19 immunization and therapeutic treatments and demand for
vaccines and antibiotics; the Company’s expectations as to
administration, manufacturing, storage and distribution; other
potential adverse impacts due to the global COVID-19 pandemic, such
as delays in regulatory review, interruptions to manufacturers and
supply chains, adverse impacts on healthcare systems and disruption
of the global economy; and general economic and market conditions
and risks, as well as other uncertainties described in our filings
with the U.S. Securities and Exchange Commission. All information
set forth in this press release is as of the date hereof. You
should consider these factors in evaluating the forward-looking
statements included in this press release and not place undue
reliance on such statements. We do not assume any obligation to
publicly provide revisions or updates to any forward-looking
statements, whether as a result of new information, future
developments or otherwise, should circumstances change, except as
otherwise required by law.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20220623005714/en/
Oragenics, Inc. Michael Sullivan, Chief Financial Officer
813-286-7900 msullivan@oragenics.com
LHA Investor Relations Tirth T. Patel 212-201-6614
tpatel@lhai.com
Oragenics (AMEX:OGEN)
Graphique Historique de l'Action
De Mar 2024 à Avr 2024
Oragenics (AMEX:OGEN)
Graphique Historique de l'Action
De Avr 2023 à Avr 2024